Gene therapy with RALA/iNOS composite nanoparticles signifcantly enhances survival in a model of metastatic prostate cancer

Recent approvals of gene therapies by the FDA and the EMA for treat-
ment of inherited disorders have further opened the door for assessment of nucleicacid pharmaceuticals for clinical usage.